As people age, they become more prone to blood clotting diseases, when blood cells called platelets clump together when they don’t need to and can cause major issues such as strokes and cardiovascular disease.
Abecma sales disappoint again as BCMA competition ramps up, FDA adcomm looms
Fourth-quarter US sales of Bristol Myers Squibb’s BCMA-targeting CAR-T therapy Abecma last year declined by 40% compared to the same period in 2022, primarily due
February 3, 2024